Zalbin albinterferon alfa-2b: Interim Phase IIb data

Interim data from an open-label, active-controlled, dose-ranging Phase IIb trial in 391 treatment-naïve patients showed that daily oral ribavirin plus monthly injections of 900, 1,200 or 1,500 ug Zalbin led to an SVR at week 12 in 76%, 75% and 81% of patients, respectively, vs. 82% of patients receiving ribavirin plus weekly injections of Pegasys peginterferon alfa-2a. Rates of serious adverse events for low, middle and high-dose Zalbin were 4%, 3% and 3%, respectively, vs. 4% for Pegasys. ...